A new study has uncovered a potential link between RNA regulation and the development of neurodegenerative diseases, such as Parkinson’s disease and dementia. This work, conducted by researchers at the University of Nottingham, used a combination of microscopy and machine learning techniques to examine the role of N6-methyladenosine modification of RNA (m6A) in the human brain.
Genentech Inc. has identified sodium channel protein type 9 subunit α (Nav1.7) channel blockers reported to be useful for the treatment of pain, depression, pruritus, cardiovascular, respiratory and psychiatric disorders.
Just three months after raising $12.9 million, Remedee Labs SAS reported it has signed a partnership with pharmaceutical group Upsa SAS to ramp commercialization of its smart bracelet for chronic pain. “We are going to rapidly deploy our non-invasive chronic pain relief technology throughout France and Europe,” David Crouzier, co-founder and CEO of Remedee Labs, told BioWorld.
High levels of bilirubin exacerbated damage to neurons in the brain caused by a stroke by binding to the TRPM2 channel, which helped regulate cell death among other processes. The research, published March 14, 2023, in Neuron, showed that blocking the binding site for bilirubin in a mouse model led to improvements in neurotoxicity suggesting some potential for the development of new stroke therapeutics.
Enveric Biosciences Inc. has announced new research detailing the first-ever isolation of a novel indolethylamine N-methyltransferase from the cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological screening of novel indolethylamines.
Vesigen Therapeutics Inc. has been awarded a grant by the Friedreich’s Ataxia Research Alliance (FARA) to develop a targeted genome editing therapeutic strategy for Friedreich’s ataxia.
High levels of bilirubin exacerbated damage to neurons in the brain caused by a stroke by binding to the TRPM2 channel, which helped regulate cell death among other processes. The research, led by Shanghai Jiao Tong University School of Medicine and the University of Toronto and published March 14, 2023, in Neuron, showed that blocking the binding site for bilirubin in a mouse model led to improvements in neurotoxicity suggesting some potential for the development of new stroke therapeutics.
Newco Teitur Trophics ApS has raised €28 million (US$30.1 million) in a series A with which it will lay out a new route to targeting sortilin in the treatment of neurodegenerative diseases. The company is targeting the sortilin-related Vps10p domain containing receptor, which plays a role in regulating a number of pathways involved in the control of neuronal viability and function.
RSS
